For patients who use medical marijuana, the Access to Cannabis for Medical Purpose Regulations makes standardized cannabis oil products — of defined quality and ratio of the key cannabinoids (THC and CBD) — available from licensed producers. This creates opportunity for optimizing the use of medical marijuana, but the current lack of robust scientific evidence constitutes a critical barrier to its dose optimization for specific indications and/or patient populations. The growing interest to use cannabis oil products for different indications and populations heightens the need for rigorous clinical and scientific investigation.
Join us as we talk about the evidence-based research that has been conducted to date at the University of Saskatchewan, on the safe and effective use of cannabis oil products.
- Jane Alcorn, Professor, College of Pharmacy and Nutrition, University of Saskatchewan
- Robert Lepairie, Assistant Professor and GlaxoSmithKline Chair in Drug Discovery and Development, College of Pharmacy and Nutrition, University of Saskatchewan
- Tim Sharbel, Professor, College of Agriculture and Bioresources, University of Saskatchewan
- Karen Tanino, Professor, College of Agriculture and Bioresources, University of Saskatchewan
- Jerome Konecsni, Executive-in-Residence, Johnson Shoyama Graduate School of Public Policy
- Peter Phillips, Distinguished Professor, Johnson Shoyama Graduate School of Public Policy; Director, Centre for the Study of Science and Innovation Policy
The Cannabinoids Research Initiative of Saskatchewan (CRIS) is an interdisciplinary research team that aims to obtain scientific evidence about the application of cannabinoids and cannabis derivatives to humans and animals for health, disease and disorders.
- 01:30 PM - 03:30 PM
- Prairie Room, 101 Diefenbaker Place, University of Saskatchewan campus; 210-2 Research Drive, University of Regina campus
- Cafe Scientifique communique